Preemptive therapy of cytomegalovirus disease in pediatric transplant recipients

被引：8

作者：

Green, M ^{[1
]}

Michaels, M ^{[1
]}

机构：

[1] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2000年 / 19卷 / 09期

关键词：

D O I：

10.1097/00006454-200009000-00012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：875 / 877

页数：3

共 13 条

[1] The role of PCR in the diagnosis and management of CMV in solid organ recipients - What is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? [J].

Abecassis, MM ;

Koffron, AJ ;

Kaplan, B ;

Buckingham, M ;

Muldoon, JP ;

Cribbins, AJ ;

Kaufman, DB ;

Fryer, JP ;

Stuart, J ;

Stuart, FP .

TRANSPLANTATION, 1997, 63 (02) :275-279

[2] Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation [J].

Boeckh, M ;

StevensAyers, T ;

Bowden, RA .

JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :907-912

[3] LOW PREDICTIVE VALUE OF POLYMERASE CHAIN-REACTION FOR DIAGNOSIS OF CYTOMEGALOVIRUS DISEASE IN LIVER-TRANSPLANT RECIPIENTS [J].

DELGADO, R ;

LUMBRERAS, C ;

ALBA, C ;

PEDRAZA, MA ;

OTERO, JR ;

GOMEZ, R ;

MORENO, E ;

NORIEGA, AR ;

PAYA, CV .

JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (07) :1876-1878

[4] Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients [J].

Falagas, ME ;

Snydman, DR ;

Ruthazer, R ;

Werner, BG ;

Griffith, J ;

Rohrer, R ;

Freeman, R ;

Fawaz, K ;

Hoffman, MA ;

Kaplan, M ;

Gill, M ;

Rubin, RH ;

Dienstag, JL ;

Doran, M ;

ORourke, E ;

Vacanti, J ;

Jenkins, R ;

Lewis, WD ;

Hammer, S ;

Martin, M ;

Fairchild, R ;

Werner, BG ;

Grady, GF ;

Leszczynski, J ;

Dougherty, N ;

Katz, A ;

Fausett, G ;

Platt, R ;

Cheeseman, SH ;

Pasternack, M ;

Gorbach, SL .

CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :824-829

[5] QUANTITATION OF HUMAN CYTOMEGALOVIRUS DNA IN BONE-MARROW TRANSPLANT RECIPIENTS [J].

GERNA, G ;

FURIONE, M ;

BALDANTI, F ;

PERCIVALLE, E ;

COMOLI, P ;

LOCATELLI, F .

BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (03) :674-683

[6] Human cytomegalovirus (HCMV) leukodnaemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection [J].

Gerna, G ;

Zavattoni, M ;

Baldanti, F ;

Sarasini, A ;

Chezzi, L ;

Grossi, P ;

Revello, MG .

TRANSPLANTATION, 1998, 65 (10) :1378-1385

[7] Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification [J].

Gerna, G ;

Baldanti, F ;

Middeldorp, JM ;

Furione, M ;

Zavattoni, M ;

Lilleri, D ;

Revello, MG .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (04) :902-911

[8] EARLY TREATMENT WITH GANCICLOVIR TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].

GOODRICH, JM ;

MORI, M ;

GLEAVES, CA ;

DUMOND, C ;

CAYS, M ;

EBELING, DF ;

BUHLES, WC ;

DEARMOND, B ;

MEYERS, JD .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1601-1607

[9]

GROSSI P, 1995, TRANSPLANTATION, V59, P847

[10]

Kusne S, 1999, Transpl Infect Dis, V1, P187, DOI 10.1034/j.1399-3062.1999.010307.x

← 1 2 →